AzTrials
AzTrials

Alcohol Use Disorder (AUD)NCT07036055

Research on the Heart-Brain Coupling Mechanisms and Interventions for Emotional Inhibitory Control Deficits in Individuals With Alcohol Use Disorder

A study testing Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) and Mindfulness Training in people with Alcohol Use Disorder (AUD), run by Shanghai Mental Health Center at 1 site in China.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The goal of this clinical trial is to understand whether combining transcutaneous auricular vagus nerve stimulation (taVNS) with mindfulness training can improve emotional inhibitory control in adults with Alcohol Use Disorder (AUD). Read more about this study

Who is it for?
Ages 18 to 55 years, men only
Conditions the study is for
Alcohol Use Disorder (AUD)
What is being tested?
Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) and Mindfulness Training
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
60 participants
Where
1 siteChina
Study dates
15 Mar 2024to 31 Aug 2024
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 55 years
  • Men only
  • No healthy volunteers
  • Adult

Who may be able to join

  • Meets DSM-5 diagnostic criteria for Alcohol Use Disorder (AUD).
  • Aged 18-55 years.
  • Currently in the post-acute withdrawal phase (≥2 weeks since last alcohol use).
  • No severe psychiatric comorbidities (e.g., schizophrenia, bipolar disorder).
  • No neurological disorders (e.g., epilepsy, traumatic brain injury).
  • Willing to provide informed consent.

Who cannot join

  • Dependence on other substances (except nicotine).
  • Severe physical illness requiring immediate treatment.
  • Active infectious diseases (e.g., HIV, hepatitis).
  • Inability to complete study procedures (e.g., cognitive impairment).
  • (For healthy controls in Study 1, inclusion required AUDIT score ≤8, no psychiatric/neurological history, and matched demographics.)

Trial locations and contacts

1 site in 1 country.

China1 site
  • China

    Mengzi, Yunnan, 661199

Other trials in China

About this study

Official title: Targeting Brain-Heart Coupling to Improve Emotional Inhibitory Control in Alcohol Use Disorder: Mechanistic Insights and Effects of Transcutaneous Auricular Vagus Nerve Stimulation Combined With Mindfulness Training

The goal of this clinical trial is to understand whether combining transcutaneous auricular vagus nerve stimulation (taVNS) with mindfulness training can improve emotional inhibitory control in adults with Alcohol Use Disorder (AUD). The study also aims to explore the brain-heart coupling mechanisms underlying these control deficits.

The main questions it aims to answer are:

Read more

Do individuals with AUD have abnormal brain-heart coupling associated with impaired emotional inhibitory control? Can taVNS combined with mindfulness training enhance emotional inhibitory control in individuals with AUD compared to sham stimulation? Researchers will compare a group receiving taVNS plus mindfulness training to a group receiving sham stimulation plus mindfulness training to see whether the active intervention improves behavioral performance and brain-heart coupling.

Participants will:

Complete an emotional Go/NoGo task while EEG and ECG data are recorded Receive 10 days of either real or sham taVNS combined with mindfulness training Complete questionnaires and cognitive assessments before and after the intervention

Read the detailed description

This two-part clinical study investigates the mechanisms and intervention effects related to emotional inhibitory control deficits in individuals with Alcohol Use Disorder (AUD), with a specific focus on brain-heart coupling (also referred to as brain-heart interplay, BHI). The study aims to identify the neurophysiological characteristics underlying inhibitory control impairments in AUD and evaluate whether non-invasive vagus nerve stimulation combined with mindfulness training can enhance emotional regulation and cognitive function.

Study 1: Mechanism Exploration Study 1 adopts a case-control observational design. A total of 28 individuals diagnosed with AUD (based on DSM-5 criteria) and 28 age- and education-matched healthy controls are recruited. Participants complete an emotional Go/NoGo task under EEG-ECG hyperscanning. Emotional inhibitory control performance is assessed through behavioral indices (reaction time, error rate) and further analyzed using the Hierarchical Drift Diffusion Model (HDDM) to quantify latent cognitive processing parameters (e.g., drift rate, boundary separation, non-decision time). Brain-heart coupling is evaluated through resting-state EEG-ECG data using multiscale coupling coefficients and maximal information coefficient (MIC) between heart rate variability (HRV) and cortical oscillations (particularly α, β, and θ bands).

Primary outcomes include:

Drift rate and inhibitory control accuracy under emotional interference Degree of BHI (HRV-EEG coupling strength and directionality) The moderating effect of self-reported emotion regulation ability (measured via DERS)

Study 2: Intervention Evaluation

Study 2 is a single-blind randomized controlled trial (RCT) involving 60 AUD participants randomly assigned to:

Active group (n=30): taVNS combined with mindfulness training Control group (n=30): sham stimulation combined with mindfulness training Participants in both groups receive daily 30-minute sessions for 10 consecutive days. taVNS is delivered using a wearable ear-clip device targeting the auricular branch of the vagus nerve (cymba conchae), with stimulation parameters set at 25 Hz, pulse width of 200 μs, and intensity adjusted to individual sensory threshold. Mindfulness training is conducted by a trained therapist, focusing on breath awareness and body scanning.

Outcome measures are collected pre- and post-intervention and include:

Emotional inhibitory control performance under the Go/NoGo paradigm HDDM-derived cognitive parameters (e.g., drift rate) EEG-ECG-based BHI metrics (HRV-EEG coupling during rest) Self-reported anxiety (GAD-7), depressive symptoms (PHQ-9), and alcohol craving Adverse events monitoring and adherence logs Data Acquisition and Processing EEG signals are recorded using a 64-channel portable system (10-20 system); ECG is simultaneously recorded.

Signals are preprocessed in EEGLAB (bandpass filtering, artifact correction via ASR), with HRV features extracted via Kubios.

HDDM modeling is conducted in Python (Bayesian MCMC estimation), and BHI is analyzed through mutual information, MIC, and transfer entropy metrics.

Sample Size and Statistical Plan Sample size was estimated based on prior effect sizes observed in similar taVNS and mindfulness interventions. Power analysis indicated 28 subjects per group achieves >80% power to detect moderate group × time interaction effects.

Statistical analyses include:

Mixed-effects ANOVA for behavioral and neural outcomes Regression models to assess mediation and moderation effects (e.g., emotion regulation ability) Pearson/Spearman correlation between physiological and behavioral measures All analyses follow intention-to-treat principles with imputation for missing data where appropriate (e.g., multiple imputation for <10% missing).

Being tested
Transcutaneous Auricular Vagus Nerve Stimulation (taVNS), Sham Stimulation, Mindfulness Training
Keywords
Alcohol Use Disorder (AUD), transcutaneous auricular vagus nerve stimulation (taVNS), brain-heart coupling, mindfulness meditation
Medical subject headings
Alcoholism

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Transcutaneous Auricular Vagus Nerve Stimulation (taVNS)Device

    Also called taVNS, Auricular Vagus Nerve Stimulation

    Participants receive transcutaneous auricular vagus nerve stimulation (taVNS) via a non-invasive ear-clip device targeting the cymba conchae. The device delivers electrical pulses at 25 Hz frequency with a pulse width of 200 µs, for 30 minutes daily over 10 consecutive days. The stimulation intensity is individually adjusted to the participant's perceptual threshold. taVNS is paired with standardized mindfulness training in this arm.

  • Sham StimulationDevice

    Participants in this group use the same device as in the active taVNS condition, but the stimulation is deactivated. The ear-clip device is placed identically on the cymba conchae, with no electrical current delivered. This sham procedure mimics the look and feel of taVNS but serves as a placebo control. Sham stimulation is combined with the same mindfulness training as the experimental group.

  • Mindfulness TrainingBehavioural

    Also called Mindfulness Meditation, Guided Mindfulness Practice

    Participants receive instructor-led mindfulness training conducted by a trained therapist. Each session lasts 30 minutes and focuses on breath awareness, body scanning, and non-judgmental awareness of internal experience. All participants (both taVNS and sham groups) receive this training daily for 10 consecutive days.

Study groups in NCT07036055
Study groupRoleWhat they receive
taVNS + Mindfulness TrainingExperimentalParticipants in this group will receive 30-minute daily sessions of transcutaneous auricular vagus nerve stimulation (taVNS) combined with standardized mindfulness training for 10 consecutive days. taVNS is delivered using a wearable device targeting the cymba conchae area of the ear. Stimulation parameters include a frequency of 25 Hz and a pulse width of 200 µs. Mindfulness training involves guided audio practice focused on breath awareness and body scanning.
Receives: Device: Transcutaneous Auricular Vagus Nerve Stimulation (taVNS); Behavioral: Mindfulness Training
Sham Stimulation + Mindfulness TrainingSham comparatorParticipants in this group will receive 30-minute daily sessions of sham stimulation (identical device without active current) combined with the same mindfulness training protocol as the experimental group, administered for 10 consecutive days. The sham stimulation mimics the appearance and procedure of active taVNS but delivers no electrical stimulation.
Receives: Device: Sham Stimulation; Behavioral: Mindfulness Training

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Emotional Inhibitory Control Performance in Emotional Go/NoGo Task

    Emotional inhibitory control performance will be assessed based on participants' accuracy in the emotional Go/NoGo task (i.e., proportion of correctly inhibited responses on NoGo trials). The task uses emotionally valenced facial stimuli and requires participants to withhold responses under emotional interference. Accuracy reflects participants' inhibitory control under affective load, which is the primary behavioral index of intervention efficacy.

    Measured: Assessed at baseline (Day 0) and post-intervention (Day 11)

Secondary outcomes (4)
  1. Drift Rate Estimated by Hierarchical Drift Diffusion Model (HDDM)

    Drift rate, a latent parameter derived from the HDDM, reflects the efficiency of cognitive processing and evidence accumulation during the Go/NoGo task. Higher drift rate indicates more efficient response selection under emotional conflict. HDDM modeling is conducted using trial-level reaction time and accuracy data.

    Measured: Assessed at baseline (Day 0) and post-intervention (Day 11)

  2. Brain-Heart Coupling Strength (HRV-EEG Coupling)

    Degree of brain-heart coupling is measured by calculating multiscale mutual information and maximal information coefficient (MIC) between heart rate variability (HRV) and EEG oscillations (particularly in the alpha, beta, and theta bands) during resting-state data collection. Higher coupling indicates stronger brain-autonomic integration.

    Measured: Assessed at baseline (Day 0) and post-intervention (Day 11)

  3. Self-Reported Emotion Regulation Ability (DERS Score)

    Participants complete the Difficulties in Emotion Regulation Scale (DERS), which provides a total score and subscale scores reflecting emotional awareness, impulse control, and clarity. Lower scores reflect better emotion regulation capacity.

    Measured: Assessed at baseline (Day 0) and post-intervention (Day 11)

  4. Alcohol Craving (Visual Analog Scale)

    Alcohol craving is measured using a visual analog scale (VAS, 0-100), with higher scores indicating stronger desire to consume alcohol. This outcome reflects emotional-behavioral change after intervention.

    Measured: Assessed at Day 0, Day 3, Day 6, Day 11

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted25 Jun 2025
  2. Study start15 Mar 2024
  3. Primary completion31 Aug 2024
  4. Study completion31 Aug 2024

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Single blind
Who is masked
Participant
Enrolment
60 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07036055
Sponsor's protocol ID
JDu-015
Status last verified
Jun 2025
First submitted
16 Jun 2025
Last updated
25 Jun 2025
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: Individual participant data (IPD) that underlie the published results, including behavioral performance, physiological signals (EEG/ECG), and questionnaire scores, will be shared in de-identified form. Data dictionaries will also be provided.

Questions about this trial

What is this clinical trial studying?

A study testing Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) and Mindfulness Training in people with Alcohol Use Disorder (AUD), run by Shanghai Mental Health Center at 1 site in China.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 25 Jun 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Emotional Inhibitory Control Performance in Emotional Go/NoGo Task (time frame: Assessed at baseline (Day 0) and post-intervention (Day 11)). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Jun 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in